Compare Cassava Sciences Inc (FLNA) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Southwest Airlines Co — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Southwest Airlines Co trades at $41.41 (market cap $20.23B). The key difference: Southwest Airlines Co is far larger — about 513.5× Cassava Sciences Inc's market cap, and Southwest Airlines Co pays a 1.74% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Southwest Airlines Co for 65 Days on average.
| FLNA | LUV | |
|---|---|---|
Market Cap | $39.40M | $20.23B |
Volume | 759,018 | 14,560,422 |
Sector | Health | Industrials |
52-Week High | $4.64 | $54.80 |
52-Week Low | $0.68 | $29.67 |
Typical Hold Time | 37 Days | 65 Days |
Enterprise Value | -$43.28M | $23.33B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Southwest Airlines (LUV) trades at $41.72, down 1.72% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth from $28.06B in 2025 to projected $30.1B in 2026, though net margins remain thin at 2.78%. Recent earnings show volatility with a Q2 2026 beat but Q1 2026 miss, while analyst consensus leans slightly bullish with a $49.61 price target representing 19% upside potential.
LUV presents a transformation story with new revenue initiatives driving growth, but faces headwinds from high fuel costs and competitive pressures. The stock offers value with reasonable P/E of 26.08 and P/S of 0.73, though investors should monitor execution of commercial initiatives and fuel cost management. Near-term catalyst includes Q3 2026 earnings release on October 21, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
